Key Highlights

  • Shares are trading up about 9.76% today, extending a rally from earlier this month.
  • The company entered a $100 million accelerated share repurchase agreement with JPMorgan.
  • An initial delivery covers approximately 80% of total expected shares under the agreement.
  • Final settlement is expected no later than the first quarter of 2027.
  • About $100 million will remain available under the company's broader buyback authorization.

iRhythm Holdings (NASDAQ:IRTC) shares are trading higher today, extending a rally following the company's announcement of a $100 million accelerated share repurchase agreement with JPMorgan Chase Bank. iRhythm is a digital healthcare company that provides ambulatory cardiac monitoring through its Zio biosensor platform, combining wearable patch devices with cloud-based analytics and an FDA-cleared deep-learning algorithm.

New Agreement Builds on Broader Buyback Authorization

Under the agreement, iRhythm made an initial payment of $100 million to JPMorgan and received an initial delivery of shares representing approximately 80% of the total expected to be repurchased. The final number of shares will be determined based on the volume-weighted average price of the stock during the agreement's term, with final settlement expected no later than the first quarter of 2027.

Move Builds on Momentum From Earlier This Month

The agreement follows the company's board-approved authorization of up to $200 million in repurchases disclosed earlier this month, which it framed as confidence in its core Business and the growth opportunity from its recently acquired VitalConnect platform. Following completion of the new agreement, the company will have approximately $100 million remaining available under that broader authorization.

Buyback Comes After a Rough Stretch Following Q3 Results

The repurchase activity follows a difficult stretch for the stock after third-quarter results showed flat Revenue for its core Zio AT monitoring product while customers awaited VitalConnect integration, with guidance also reflecting a modest cut. Several analysts had trimmed price targets following that report, even as some maintained bullish ratings on the stock.

What Comes Next for the Repurchase Program

Investors are likely to watch for confirmation of final settlement under the new agreement and further detail on VitalConnect integration progress as the next catalysts shaping sentiment toward the stock.